The PCA3 test measures the expression of prostate cancer gene 3 (PCA3) mRNA in urine samples. PCA3 is specific to the prostate and is significantly up-regulated (60-100 fold) in prostate cancer. The test quantitatively measures PCA3 mRNA as well as PSA mRNA and determines their ratio. High ratios have been shown to be indicative of prostate cancer. Warnex claimed to be the first laboratory to offer this service in Canada.
Mark Busgang, president and CEO of Warnex, said: “We are pleased to offer this new prostate cancer screening assay, which is highly specific and more precise than all other available screening tests for the detection of prostate cancer. The addition of this service to Warnex Medical Laboratories’s service offering is part of our strategy to focus on specialized medical testing for the healthcare industry using advanced technologies.”